Just six short weeks ago, we reported on the launch of SRAM’s long-awaited Mechanical Transmission mountain bike drivetrains, Eagle 90 and Eagle 70. For many, especially those who have lamented the ...

OxPay SG, a subsidiary of OxPay Financial, appoints Chin Mun Chung as COO, and awaits MAS approval for his appointment as CEO ...

Investors interested in stocks from the Insurance - Property and Casualty sector have probably already heard of Axis Capital (AXS) and Chubb (CB). But which of these two stocks is more attractive ...

Dignity Health Arena is set to host the Lisa Lisa 40th Anniversary Tour on Friday, October 17, 2025. The concert, featuring ...

DAHON, a global leader in the folding bike industry, showcased its vision for the future of cycling at China Cycle 2025, ...

New Zealand pop-alt singer Lorde is making a huge comeback this autumn with her world wide Ultrasound tour. The Royals artist ...

WWE is bringing John Cena back to the ring for his final ever live shows this year while on the Road to Clash in Paris event.

Axsome Therapeutics reports 62% YoY revenue growth in Q1 2025, fueled by Auvelity & Sunosi. Key milestones include Symbravo launch & AXS-14 FDA decision.

Axis Capital Holdings AXS +0.34% + Free Alerts has outperformed the market over the past 5 years by 7.48% on an annualized ...

Axsome submitted an NDA for AXS-14 for fibromyalgia and anticipates FDA acceptance in Q2 2025. Additionally, the company plans to submit a supplemental NDA for AXS-05 in Alzheimer's disease ...

Axis Capital Holdings Ltd (AXS) reports robust earnings growth and record premiums despite facing competitive pressures and ...